EU Accelerated Assessment Tracker

Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.

This tracker provides information on accelerated assessment requests for planned marketing authorization applications (MAAs) that have come before the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for a decision. It also tracks whether companies retain fast-track status for MAAs as they make their way through the EU centralized drug evaluation procedure.

This latest update (see table at the end of this article) reflects recent developments.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from European Performance Tracker

  • EU Accelerated Assessment Tracker

    Decisions on sponsor requests for accelerated assessment of planned EU marketing authorization applications that will be reviewed by the European Medicines Agency’s human medicines committee (the CHMP) as well as information on whether MAAs granted accelerated assessment retain fast-track status as they make their way through the EU centralized procedure. Updated monthly.

  • EU Approvals

    Products containing new active substances that have been approved for marketing in the EU under the EU’s centralized authorization procedure. Updated monthly.

  • EU Filings

    New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

More from Regulatory Trackers